Curriculum Vitae Emmanuel SERONT
Last name: SERONT
First name: Emmanuel
Birth date and place: 24/07/1979, La Louvière, Belgium
Adress: Chaussée de Tubize 121, 1440 Braine le Chateau, Belgium
Tel : +32 475/ 942047
Universitary cursus
First Doctorat: Magna Cum Laude, June 2001
Second Doctorat: Magna Cum Laude, June 2002
Third Doctorat: Magna Cum Laude, June 2003
Fourth Doctorat: Magna Cum Laude, June 2004
EKG certificate, June 2003
Medical Doctor , June 2004 with Magna Cum Laude
Doctor in pharmaceutical and biomedical science (PhD), November 2013
Internal Medicine Fellowship





2004-2005 : Hopital de Jolimont, Dr Derue, Haine Saint Pierre, Belgium
2005-2006 : Hopital de Gilly, Dr Mineur , Gilly, Belgium
2006-2007 : Hopital Universitaire Saint Luc, Medical Oncology, Prof Machiels, Belgium
2007-2008 : Hopital Universitaire Saint Luc, Nephrology unit, Prof Jadoul, Belgium
2008-2008 : Hopital Universitaire Saint Luc, Intensive care Unit, Prof Laterre
Oncology Fellowship
 2008-2009 : Hopital Universitaire Saint Luc, Medical Oncology, Prof Machiels
 2009- 2013: Training Fellow in fondamental research in oncology and experimental
pharmacotherapy with a PhD project “ Role of mTOR inhibitor in cancer; link with
autophagy, hypoxia and angiogenesis.”
Postgraduate Course of Medical Oncology, National Oncology Examination
2009= 83%
2010= 85%
2011= 86%
Certificate of Good Clinical Research Practice (April 2013)
Certificat universitaire en science et médecine des animaux de laboratoire, « Maître en
expérimentation animale » UCL
Diploma of Doctor in Pharmaceutical and Biomedical Sciences (PhD) 19 Novembre 2013
“Dealing with resistances to mTOR inhibitors in bladder and breast cancer. “
Thesis presented in November 2013 at UCL, Brussel.
Promoter: Prof Feron O. and Machiels JP.
Formation légale en science et médecine des animaux de laboratoire (Février 2010)
Diplôme de “Maîtrise d’expérience” en expérimentation animale (June 2010)
Publications

About two intra aortic masses.
E. Seront, G. de Saint Hubert, Derue G. European Journal of Internal Medicine, 2008

Targeted therapy in metastatic renal cell carcinoma.
E. Seront, JP Machiels. Journal of Belgian Society of Medical Oncology, January
2008.

Review of angiogenesis inhibitors in renal cell carcinoma.
E. Seront, JP Machiels. Recent Patents Anticancer Drug Discov, June 2009

Successful long-term management of a patient with late-stage metastatic
colorectal cancer treated with panitumumab.
E. Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y. Cancer Treat Rev.
2010 Feb;36 Suppl 1:S11-4.
 Update in malignant Melanoma.
E. Seront and JF Baurain. Journal of Belgian Society of Medical Oncology, May 2010.
 New therapeutic perspective in renal cell carcinoma: Everolimus.
E. Seront and JP Machiels. Louvain Medical 2010
 New drugs in medical oncology: new difficulties to distinguish drug-induced side
effects from cancer complications: a case-report.
E. Seront, F. Mazzeo, M. Mano, JP Machiels, JF Baurain. Acta Clinica Belgica 2011
 Liver-Directed Therapies: Does It Make Sense in the Current Therapeutic
Strategy for Patients With Confined Liver Colorectal Metastases?
E. Seront, Van den Eynde M. Clin Colorectal Cancer. 2012
 Phase II trial of Everolimus monotherapy in the palliative treatment of patients
with metastatic Transitional Cell Carcinoma after failure of platinum-based
therapy: activity and biomarkers.
E. Seront, S. Rottey, B. Sautois, L. A. D'Hondt, J. L. R. Canon, J. M. Vandenbulcke,
N. Whenham, J. C. Goeminne, O. Feron, J. P. H. Machiels. Annals Oncology 2012
 PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in
human bladder cancer through the unhampered feedback loop driving PI3K/Akt
activation.
E. Seront, A. Pinto, C. Bouzin, JP Machiels, O. Feron. British Journal of Cancer
September 2013.
 Tumour hypoxia determines the potential of combining mTOR and autophagy
inhibitors to treat mammary tumours.
E. Seront, R. Boidot, O. Karroum, C. Bouzin, JP Machiels, O. Feron. British Journal
of Cancer November 2013
 Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent
inhibitors of lactate influx but not efflux.
Draoui N, Schicke O, E. Seront , Bouzin C, Sonveaux P, Riant O, Feron O.
Molecular Cancer Therapeutic March 2014
 Molecular biology and targeted therapies for urothelial carcinoma.
Seront E, Machiels JP. Cancer Treatment Review 2015
 Uptdates in Renal Cell carcinoma : new targeted therapies and new toxicities.
E. Seront , JP Machiels. Book Chapter, Recent Patent Anticancer Drugs Discoveries
2012.
 Translation and Its Regulation in Cancer Biology and Medicine. A. Parsyan, E.
Seront, JP Machiels. Book on Translation and Its Regulation in Cancer Biology and
Medicine 2014.
 Venous Malformation: from causative mutations to murine model and targeted
therapy. E. Boscolo, N. Limaye, L. Huang, K. Kang, J. Soblet, M. Uebelhoer, A.
Mendola, M. Natynki, E. Seront, S. Dupont, J. Hammer, C. Legrand, C. Brugnara, L.
Eklund, M. Vikkula, J. Bischoff, L. Boon. Journal of Clinical Investigation 2015.
 Rapid and fatal acute heart failure induced by pazopanib. van Marcke C, Ledoux
B, Petit B, Seront E. British Medical Journal Case Rep 2015

 Rapamycin as Novel Treatment for Refractory-to-Standard-Care Slow-Flow
Vascular Malformations. Boon LM, Hammer J, Seront E, Dupont S, Hammer F,
Clapuyt P, Vikkula M. Plast Reconstr Surg. 2015
Abstract, poster and oral presentation

Factor V and prothrombin polymorphysm in patients aged 75 years or older.
Abstract E. Seront, J. Yango, O. Descamps. Acta Clinica Belgica, Vol 60 2005.
 Phase II trial of RAD001 monotherapy in the palliative treatment of patients with
metastatic Transitional Cell Carcinoma after failure of platinum-based therapy.
American Society of Clinical Oncology 2010 (Chicago), abstract
 Phase II trial of Everolimus monotherapy in the palliative treatment of patients
with metastatic Transitional Cell Carcinoma after failure of platinum-based
therapy: activity and biomarkers. American Society of Clinical Oncology 2011
(Chicago), Poster session.

Phase II trial of Everolimus monotherapy in the palliative treatment of patients
with metastatic Transitional Cell Carcinoma after failure of platinum-based
therapy: activity and biomarkers. Belgian society of Medical Oncology 2011, oral
presentation.
 Angiogenesis-related cytokines as potential predictive biomarkers in a phase II
trial evaluating everolimus efficacy in locally advanced or metastatic Transitional
Carcinoma Cell. Fifth European Organisation for Research and Treatment of Cancer
(EORTC))/National Cancer Institute (NCI)/American Society of Clinical Oncology
(ASCO) annual meeting on Molecular Markers in Cancer, Brussels 2011, poster
session.
 Translational research; analysis of RAD001 efficacy in patients with metastatic
transitional cell carcinoma. Fond National de la Recherche Scientifique - Télévie
2012 Liège, oral presentation
 About translational research in metastatic bladder cancer. European Urology Tour
2012 Brussel, oral presentation
 Role of Akt activation induced by mTOR inhibitors in development of resistance
to mTOR inhibitors. Belgian Association of Cancer Research 2013, oral
presentation.

Role of Akt activation induced by mTOR inhibitors in development of resistance
to mTOR inhibitors. Belgian Society of Medical Oncology 2013, oral presentation.
 Hypoxia decreases efficacy of mTOR inhibitors in MCF-7: role of autophagy
Belgian Association Cancer Research 2013 Antwerpen, poster presentation
 Role of autophagy in cancer cells resistance to mTOR inhibitors. Télévie 2012
Brussel, oral presentation and poster session
 Multidisciplinary symposium Head and Neck symposium June 2014, oral
presentation.
 Multidisciplinary symposium Head and Neck symposium May 2015, oral
presentation.
 Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of
rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or
metastatic transitional cell carcinoma (TCC). American Society of Clinical
Oncology 2015 (Chicago), abstract
 Randomized phase II study of cabazitaxel versus methotrexate in patients with
recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
previously treated with platinum-based therapy. American Society of Clinical
Oncology 2015 (Chicago), Poster presentation.
 Preceptorship Program on Prostate Cancer June 2015 (Cliniques Saint Luc)
 Definitive chemoradiotherapy with either high-dose or weekly cisplatin in
patients with locally advanced squamous cell head and neck cancer: A
retrospective analysis. European Society of Medical Oncology congress 2015,
Vienna. Poster presentation
Awards

Phase II trial of Everolimus monotherapy in the palliative treatment of patients
with metastatic Transitional Cell Carcinoma after failure of platinum-based
therapy: activity and biomarkers. American Society of Clinical Oncology 2011
(Chicago), Poster session 2011. Oral presentation Belgian society of Medical
Oncology, Junior Presentation Awards le 19 février 2011. First Award

Role of Akt activation induced by mTOR inhibitors in development of resistance
to mTOR inhibitors. Belgian Society of Medical Oncology 2013, oral presentation.
First Award

Role of Akt activation induced by mTOR inhibitors in development of resistance
to mTOR inhibitors. Belgian Association of Cancer Research 2013, oral
presentation. Second Award
 Pfizer Educational Grant. December 2013
 John Mulliken Award for Best Scientific Paper: Venous Malformation: from
causative TIE2 mutations to murine model and targeted therapy. E. Boscolo, K.
Kang, N. Limaye, J. Soblet, M. Uebelhoer, M. Natynki, C. Brugnara, E. Seront, L.
Eklund, M. Vikkula, L. Boon. February 2015
Association Member
 American Society of Clinical Oncology (ASCO) member (2013)
 European Society of Medical Oncology (ESMO) member (2014)
 Belgian Society of Medical Oncology (BSMO) member (2013)
Current Position
 Medical oncologist at Hôpital de Jolimont, Groupe Jolimont (2/10/2013 till present)
 Head of Breast Clinic Hôpital de Nivelles (groupe Jolimont)
 Medical oncologist, Cliniques Universitaires Saint Luc, Brussel (consultant externe)
(2/10/2013 till present)
 Chargé de cours infirmier en Oncologie pour Haute Ecole Louvain en Hainaut
(HeLHA)
 Referent oncologist for the vascular malformation center (VASCAPA) in Cliniques
universitaires Saint Luc, Brussels, Belgium